Pre-exposure prophylaxis, widely known as PrEP, refers to the use of certain antiretroviral medicines by people who do not have HIV but are at ongoing risk of exposure. The core idea behind PrEP is simple: maintain a steady level of medication in the body so that HIV is less able to establish infection if exposure occurs, according to guidance from major public health agencies. This article explains Everything You Need to Know about Prep in a neutral, evidence-based way, covering Impact of Prep on Hiv, PrEP Medication Options, and how these choices fit into the wider Clinical Management of Hiv.
PrEP is not a single product. It includes daily oral tablets, injections given at regular intervals, and experimental long-acting delivery systems such as an HIV implant under the skin. These options aim to support different preferences and clinical needs. PrEP is not a cure and is not used to treat people who already have HIV; instead, it is one part of combination prevention, alongside regular testing for HIV and other sexually transmitted infections (STIs), counseling, and risk-reduction planning.
PrEP uses antiretroviral drugs, similar to those used for HIV treatment, but taken by HIV-negative individuals before exposure. Public health guidance defines PrEP as a preventive intervention that can be given as pills or injections. The Impact of Prep on Hiv prevention is based on drug levels that block key steps in the HIV life cycle if the virus enters the body. For example, combinations like emtricitabine with tenofovir target reverse transcription, a process the virus needs to replicate. By lowering the likelihood that HIV will establish a permanent infection after exposure, PrEP has become part of national and global HIV prevention strategies.
Multiple large trials and ongoing surveillance have found that PrEP significantly reduces new HIV infections among people who take it as prescribed. For example, long-acting injectable cabotegravir (marketed as Apretude) was associated with a 69 percent lower rate of HIV acquisition compared with daily oral tenofovir disoproxil fumarate/emtricitabine in one trial of cisgender men and transgender women, and a 90 percent lower rate in a trial of cisgender women. More recent studies of lenacapavir, a capsid inhibitor now authorized in some regions for PrEP dosing every six months, reported 96 to 100 percent relative risk reduction in different study populations over about one year of follow-up. These results indicate that PrEP, when used appropriately, can play a major role in reducing community-level transmission.
PrEP Medication Options currently include daily oral tablets, long-acting intramuscular or subcutaneous injections, and investigational long-duration delivery systems that could be placed under the skin, sometimes described as an Hiv Implant. Selecting among these options is typically based on medical history, route of anticipated HIV exposure, kidney function, and ability to attend follow-up visits.
Two oral PrEP tablets have regulatory approval in many countries: emtricitabine/tenofovir disoproxil fumarate (often referred to as TDF/FTC) and emtricitabine/tenofovir alafenamide (TAF/FTC). Both are taken once daily. These combinations supply drug levels in blood and tissues that can prevent HIV from establishing infection after sexual exposure. Current labeling for TAF/FTC (sometimes known by the brand Descovy) excludes protection for people at risk through receptive vaginal sex, because efficacy data in that specific exposure route have not yet been established at the time of approval. Clinical guidance recommends that people starting daily oral PrEP receive baseline HIV testing, kidney function testing, and STI screening, then return roughly every three months for repeat HIV tests, prescription refills, and risk assessment. Monitoring renal function is emphasized, particularly with regimens containing TDF, because tenofovir can affect kidney function in some individuals.
Cabotegravir long-acting (CAB-LA), given first as oral lead-in for some regimens and then as intramuscular injections, was the first injectable PrEP option approved by the U.S. Food and Drug Administration. After two initiation doses one month apart, CAB-LA is typically administered every two months in a clinic. Injectable PrEP may be useful for people who prefer not to take a daily pill, who have difficulty maintaining daily adherence, or who want a discreet schedule aligned with clinic visits. Ongoing clinical management includes HIV testing at each injection visit to confirm that the person remains HIV-negative, screening for STIs, and counseling on what is sometimes called the “tail period” after stopping injections. During this period, drug levels slowly decline, and partial levels could theoretically allow HIV infection with a risk of resistance, so follow-up testing continues for several months after the last injection.
Lenacapavir is a long-acting capsid inhibitor that can be delivered by subcutaneous injection. In June 2025, the U.S. FDA approved a twice-yearly lenacapavir product (marketed in some regions as Yeztugo or similar names) for HIV PrEP, and public health authorities such as the U.S. Centers for Disease Control and Prevention (CDC) have issued strong clinical recommendations for its use in eligible individuals weighing at least 35 kilograms. The World Health Organization (WHO) has also described lenacapavir injections every six months as a promising addition to global prevention strategies. Trial data showed very low numbers of new HIV infections among participants who received lenacapavir compared with those on standard daily oral PrEP. These findings suggest that longer dosing intervals may support adherence at the population level.
Researchers are also investigating the idea of a removable, refillable, or dissolvable HIV implant that slowly releases PrEP medication under the skin for many months. One studied approach uses islatravir (also known as MK-8591), placed subdermally to provide sustained drug levels suitable for PrEP for up to a year or longer in early studies. Safety reviews in 2022 led to pauses and redesigns of some islatravir PrEP programs, and development timelines have been adjusted to re-evaluate the benefit-risk profile.Although no Hiv Implant for PrEP is yet widely approved for routine use, published trial data support the scientific feasibility of an implant-based strategy as a future PrEP modality.
Clinical Management of Hiv generally refers to the full spectrum of HIV care: prevention for those who are HIV-negative, rapid diagnosis, antiretroviral therapy for people with HIV, and ongoing monitoring of viral load and overall health. PrEP fits into this framework as a pre-exposure tool. Offering PrEP routinely in primary care, sexual health clinics, and other healthcare settings is now considered standard preventive medicine in many guidelines, similar in principle to vaccination programs or chronic disease risk screening. Providers are encouraged to discuss sexual health histories and injection drug use in a routine, nonjudgmental way so that PrEP can be matched to the individual’s actual exposure routes.
PrEP is not prescribed once and forgotten. Clinical guidance recommends scheduled follow-up to confirm that the person remains HIV-negative, to monitor for side effects, and to identify any changes that might require switching PrEP Medication Options. For oral PrEP, follow-up typically occurs at least every three months. These visits can include HIV antigen/antibody tests, and in some settings HIV-1 RNA tests, because early detection of infection is important for rapid transition from PrEP to full treatment. Kidney function is assessed periodically for people taking tenofovir-based tablets, and lipid levels may be checked for those on TAF/FTC. For injectable cabotegravir given every two months, and for lenacapavir given every six months, in-clinic visits are used both to administer the medication and to conduct HIV testing and STI screening. Guidance also addresses the “tail period” after stopping long-acting PrEP, because subtherapeutic drug levels could allow HIV replication and might contribute to resistant virus if infection occurs. Care teams therefore plan follow-up testing for several months after the final injection and may temporarily recommend an oral PrEP alternative.
Adherence remains one of the main practical questions in PrEP access. Public health data show that about half of people who start daily oral PrEP stop within 6 to 12 months, which limits the overall prevention benefit. Long-acting strategies, such as every-two-month cabotegravir injections or every-six-month lenacapavir injections, were developed in part to reduce the need to remember a pill every day and to align PrEP use with scheduled clinical visits. The introduction of twice-yearly dosing has led international agencies and national health systems to evaluate cost, delivery logistics, and equitable distribution, particularly in regions with high HIV incidence. Research is also exploring refillable subcutaneous reservoirs and dissolvable implants to extend PrEP coverage to a year or longer without frequent clinic visits, although these approaches remain investigational.
PrEP shows how HIV prevention has shifted toward individualized risk management supported by ongoing clinical follow-up. The Impact of Prep on Hiv can be seen not only in trial outcomes but also in updated national guidance that now treats PrEP as routine preventive care for eligible people. As PrEP Medication Options expand from daily tablets to injections every two months, injections every six months, and potential long-acting systems such as an Hiv Implant, healthcare providers can match prevention methods to real-world patterns of exposure, adherence, and access. Ongoing Clinical Management of Hiv therefore includes both immediate treatment for people with HIV and proactive, evidence-based HIV prevention for people without HIV, delivered in a structured, monitored, and data-driven way.